ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ObsEva SA (OBSV) delivered earnings and revenue surprises of -37.93% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates

Company has six international based clinical studies moving through FDA and EU approval process.

ObsEva: Building A Top Tier Company Focused On Women's Health Issues

ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.

ObsEva Ends Recruitment in Second Uterine Fibroids Study

ObsEva SA (OBSV) CEO Ernest Loumaye on Q1 2019 Results - Earnings Call Transcript

ObsEva SA (OBSV) delivered earnings and revenue surprises of -18.00% and -50.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates

News for ObsEva Stock (OBSV)